TriMas Q3 Adjusted EPS $0.50, Sales Up 7.7%; Reaffirms FY26 Guidance, Signs Rapak Sale
TRS sits 30% above its 52-week low of $30.43.
Summary
TriMas posted Q3 adjusted EPS of $0.50 versus $0.17 a year ago on 7.7% sales growth, reaffirmed its $1.60-$1.70 full-year adjusted EPS outlook, and signed a deal to sell its Rapak bag-in-box business.
Key Events · Earnings and Guidance · TRS
-
Q3 Adjusted EPS Jumps to $0.50
Adjusted diluted EPS from continuing operations rose to $0.50 from $0.17 a year earlier, a 194.1% increase, on net sales of $178.7 million, up 7.7% year-over-year.
-
Adjusted Operating Profit Up 47.9%
Adjusted operating profit reached $13.6 million versus $9.2 million in Q3 2025, driven by cost-reduction and organizational streamlining; GAAP operating profit was $11.5 million against a $3.2 million loss a year ago.
-
FY26 Guidance Reaffirmed, Sales Outlook Raised
Full-year 2026 adjusted diluted EPS guidance held at $1.60-$1.70, while combined Packaging and Specialty Products sales growth is now expected at 4%-6%, up from the prior 3%-6%.
-
Rapak Divestiture Signed
In October 2026 the company agreed to sell Rapak, its flexible bag-in-box packaging business, with the transaction expected to close in November 2026.
Analysis · TRS · Manufacturing
TriMas delivered a clean quarter: adjusted operating profit rose 47.9% to $13.6 million on sales of $178.7 million, and adjusted diluted EPS from continuing operations jumped to $0.50 from $0.17. The company reaffirmed full-year 2026 adjusted EPS of $1.60-$1.70 and nudged its sales growth outlook up to 4%-6% from 3%-6%. The balance sheet is the real story — $1.16 billion of cash against $397.1 million of debt, a net cash position of $761.4 million left over from the $1.46 billion Aerospace sale. Management is still deciding how to deploy that cash (organic growth, acquisitions, more buybacks), and the newly signed Rapak bag-in-box divestiture, expected to close in November 2026, shows the portfolio pruning continues. The offset is Specialty Products, where operating profit fell to $0.08 million on Norris Cylinder throughput problems and unrecovered raw material costs.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TRS was trading at $39.50 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $30.43 to $45.43. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.